2022
Jensen IS, Wu E, Cyr PL , Claussen M, Winkler T, Salahuddin K, Prats J, et al. 2022. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention patients: A US hospital perspective. Am J Cardiovasc Drugs 22(1):93-104; doi: 10.1007/s40256-021-00491-9 .
View Abstract
Publication: Manuscripts
Alexander AW, Jensen IJ, Hathaway J, Srivastava K, Cyr PL , Sidonio RF, Batt K. 2022. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 28(5):518-527; doi: 10.18553/jmcp.2022.21197 .
Publication: Manuscripts
Sacks NC , Healey BE, Raza S, Cyr PL , Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576.
View Abstract
Publication: Manuscripts
Sheshadri A, Sacks NC , Healey B, Cyr P , Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659.
View Abstract
Publication: Manuscripts
Sacks NC , Healey BE, Raza S, Cyr PL , Boerner G, Sheshadri A. 2022. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States. Blood Adv 6(5):1566–1576; doi: 10.1182/bloodadvances.2021004364 .
View Abstract
Publication: Manuscripts
Sheshadri A, Sacks NC , Healey B, Cyr P , Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065 .
View Abstract
Publication: Manuscripts
Cardosi L, Rau R, Emdem MR, Kemp R, Minshall M, Pontenani F, Provision S, Sacks N . 2022. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Value in Health 25(12). Supplement. S1:S546.
View Abstract
Publication: Manuscripts
2021
Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC , Lang K, Nelson WW. 2021. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 9:2050312120986733.
View Abstract
Publication: Manuscripts
Dougherty C., Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N , Kautz S, Cyr P . Impact of INP104 on healthcare resource use among patients in STOP 301. Presentation at American Academy of Neurology Annual Meeting, Virtual, April 2021.
Publication: Abstracts and Presentations
Dougherty C., Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N , Kautz S, Cyr P. INP104 reduces self-reported ED and urgent care in patients with episodic migraine. Presentation at Academy of Managed Care Pharmacy (AMCP) annual meeting [held virtually], April 2021.
A Division of